DENGUE VIRUS: NO ONE IS SAFE

Caitlin ReedSmith CollegeApril 29, 2005

www.invivo.fiocruz.br/dengue/home_dengue.htm

OVERVIEW OF THEMES

Background Information Clinical Presentation & Diagnosis Biology Vaccination Prospects Public Health

WHAT IS DENGUE?WHAT IS DENGUE?

Flavivirus (type of arbovirus)Flavivirus (type of arbovirus)

Transmitted from Transmitted from Aedes aegyptiAedes aegypti and and Aedes albopictusAedes albopictus mosquitoes mosquitoes

Four Serotypes (Dengue 1-4)Four Serotypes (Dengue 1-4)

DENGUE (cont’d)DENGUE (cont’d) Three Manifestations:Three Manifestations:

1. Dengue Fever1. Dengue Fever2. Dengue Hemorrhagic Fever2. Dengue Hemorrhagic Fever3. Dengue Shock Syndrome3. Dengue Shock Syndrome

Leads to death in 5% of cases Leads to death in 5% of cases

More dangerous if infected second More dangerous if infected second time by different serotypetime by different serotype

WHY DO WE CARE ABOUT WHY DO WE CARE ABOUT DENGUE?DENGUE?

CDC Category A Infectious DiseaseCDC Category A Infectious Disease Infects 50-100 million people every Infects 50-100 million people every

yearyear About half the world lives in a “hot About half the world lives in a “hot

zone”zone” Very hard to create vaccineVery hard to create vaccine Mosquito evolution = Mosquito evolution =

threat to U.S. threat to U.S. Global warmingGlobal warminghttp://klab.agsci.colostate.edu/aegypti/

aegypti.html

WHY NOW?WHY NOW? Failed eradication attempt in the

Americas in 1970 Previously unestablished serotypes are

establishing themselves in various countries

Recent Outbreaks:1. India, 20032. Hawaii, 20013. Taiwan, 20014. Puerto Rico, 1994-1995

WHERE IS DENGUE WHERE IS DENGUE FOUND?FOUND?

www.traveldoctoronline.net/diseases/dengue.htm

DENGUE DENGUE TRANSMISSITRANSMISSI

ON ON

1. Mosquitoes transmitdengue to human dendriticcells

2. Dengue targets areaswith high WBC counts(liver, spleen, lymph nodes, bone marrow, andglands)

3. Dengue entersWBCs & lymphatic tissue4. Dengue enters bloodcirculation

3

4

1

2

http://phil.cdc.gov/PHIL_Images/08051999/00004/dengue_phf/sld006.htm

3

HOW DENGUE SPREADS

CLINICAL CLINICAL PRESENTATIOPRESENTATION OF DENGUEN OF DENGUE

SYMPTOMSSYMPTOMS OF DHF OF DHFGRADE I: Fever with other symptoms such as vomiting, headache, muscle and joint pain: positive tourniquet test is the only evidence of hemorrhagingGRADE II: Grade I symptoms + spontaneous bleedingGRADE III*: Failure of circulatory system, clammy skin, rapid & weak pulse, restlessnessGRADE IV*: Severe shock, no measurable blood pressure or pulse*Considered Dengue Shock Syndrome (DSS)

DENGUE GRADATIONDENGUE GRADATION

http://w3.whosea.org/en/Section10/Section332/Section554_2564.htm

http://www.cdc.gov/ncidod/dvbid/dengue/slideset/set1/images/petechiae2-small.jpg

P E T E C H I A E

P U R P U R A

http://www.pediatrics.wisc.edu/education/derm/tutb/85m.jpg

http://www-medlib.med.utah.edu/WebPath/ATHHTML/ATH036.html

E C C H Y M O S I S

http://www.cgste.mq/brainstorm/dengue/image/hemo.gif

NASAL HEMORRHAGING

BIOLOGY OF BIOLOGY OF DENGUEDENGUE

http://www.stanford.edu/group/virus/flavi/2000/deng_em.jpg

BASIC BIOLOGYBASIC BIOLOGY Single, positive-Single, positive-

stranded RNA stranded RNA surrounded by an surrounded by an icosahedral coreicosahedral core

90 glycoprotein E 90 glycoprotein E dimers overly M dimers overly M proteinsproteins

Protein E is most Protein E is most important important characteristic of characteristic of denguedengue

Modis, Ogata, Clements, et. al., 2004

BASIC DENGUE BASIC DENGUE GENOMEGENOME

http://microvet.arizona.edu/Courses/MIC419/VaccProp05html/Dengue.html

FUSION PROTEIN EFUSION PROTEIN E

Modis, Ogata, et. al., 2004.

IMMUNE IMMUNE RESPONSERESPONSE

http://www.ethal.org.my/opencms/opencms/ethal/Images/MedGeneralImages/Lymphocyte.jpg

FIRST INFECTIONFIRST INFECTION Humoral and cellular immune Humoral and cellular immune

responseresponse- Ab serum neutralizing levels increase- Ab serum neutralizing levels increase- T-lymphocytes activated by dendritic - T-lymphocytes activated by dendritic cellscells- Memory cells develop antibodies to - Memory cells develop antibodies to fight off future infection of same fight off future infection of same serotypeserotype

SECOND INFECTIONSECOND INFECTION

Antibody dependent Antibody dependent enhancementenhancement

- Enhancing immunoglobulin - Enhancing immunoglobulin G (IgG) G (IgG) antibodiesantibodies

- Fc Receptors- Fc Receptors

CELLULAR CELLULAR LEVEL OF LEVEL OF DENGUE DENGUE FUSIONFUSION

ENTRY INTO CELLENTRY INTO CELLDengue infectionDengue infection

Endosome entry & pH changeEndosome entry & pH change

E protein conformational changeE protein conformational change

Release of viral RNA into cellRelease of viral RNA into cell

Replication & further infection Replication & further infection

PRE-FUSION

POST-FUSION

PROTEIN E CONFORMATIONAL CHANGE

Modis, Ogata, et. al., 2004

PROTEIN E INSERTION PROTEIN E INSERTION INTO PMINTO PM

http://crystal.med.harvard.edu/cover_modis_vsmall.jpgModis, Ogata, et. al., 2004.

VIRAL REPLICATIONVIRAL REPLICATION

http://chen.bio.purdue.edu/images/flavi/viruslifecycle.jpg

TO TO SUMMARIZESUMMARIZE

……THE BODY’S THE BODY’S RESPONSE TO A RESPONSE TO A

DENGUE INFECTIONDENGUE INFECTION

DENGUE IN THE CELLDENGUE IN THE CELL Dendritic cell infection Dendritic cell infection T-cell T-cell

activationactivation Previous infection = increase in Previous infection = increase in

viral load and decrease in viral load and decrease in incubation periodincubation period

ADE is problem for 20 years after ADE is problem for 20 years after first infectionfirst infection

PATHOGENIC STRATEGIES PATHOGENIC STRATEGIES OF DENGUE OF DENGUE

Invades circulatory system, causing: - vascular permeability - Disseminated intravascular coagulation

- Potentially death

http://www.ehu.es/biomoleculas/PROT/blood-clot.gif

DENGUE DENGUE DIAGNOSISDIAGNOSIS

http://bensguide.gpo.gov/images/ben/ben_doctor.jpg

LABORATORY DIAGNOSIS LABORATORY DIAGNOSIS OF DENGUEOF DENGUE

METHODS: 1. Viral Isolation &

Characterization

2. Genomic Sequencing

3. Antibody Detectionwww.synergene.net/de/images/dnasmall.jpg

VIRAL ISOLATION & VIRAL ISOLATION & CHARACTERIZATIONCHARACTERIZATION

Old “Gold Standard”Old “Gold Standard” Cell Culture (mammals Cell Culture (mammals

& mosquitoes)& mosquitoes)-Indirect -Indirect ImmunofluorescenceImmunofluorescence

Useful to study basic Useful to study basic virology, epidemiology,virology, epidemiology,and pathogenesisand pathogenesis

Impractical for rapid Impractical for rapid diagnosis & treatmentdiagnosis & treatment

http://www.cdc.gov/ncidod/dvbid/dengue/slideset/set1/image/virus-isolation-cell-culture2.jpg

GENOMIC SEQUENCINGGENOMIC SEQUENCING Quicker, more reliable Quicker, more reliable

means of diagnosismeans of diagnosis NASBA method (RNA-NASBA method (RNA-

specific amplification assay)specific amplification assay) RT-PCR method to provide RT-PCR method to provide

most accuracy, uses 5’-3’ most accuracy, uses 5’-3’ nuclease oligonucleotide nuclease oligonucleotide probe (which may not be probe (which may not be able to distinguish among able to distinguish among serotypes) – new “Gold serotypes) – new “Gold Standard”Standard”

Beware of false-positives Beware of false-positives due to contaminationdue to contamination

http://animal.intron.co.kr/Image/RT-pcr.gif

ANTIBODY DETECTIONANTIBODY DETECTION Most common Most common

methodsmethods1. Hemagglutinin 1. Hemagglutinin inhibition test (HI test)inhibition test (HI test)

2. ELISA2. ELISA

3. Rapid 3. Rapid immunochromatograpimmunochromatography test hy test (commercial kits (commercial kits available) available)

http://webdb.dmsc.moph.go.th/ifc_nih/applications/pics/Qualitative_test.jpg

VACCINE VACCINE DEVELOPMENT AND DEVELOPMENT AND

PUBLIC HEALTH PUBLIC HEALTH STRATEGIESSTRATEGIES

STOPPING STOPPING DENGUEDENGUE

MOST PROMISING MOST PROMISING VACCINEVACCINE

ChimeriVax-ChimeriVax-DengueDengue- Tetravalent- Tetravalent- Uses yellow fever - Uses yellow fever vaccine as base vaccine as base- 92% of monkeys - 92% of monkeys passed “virulent passed “virulent virus virus challenge”challenge”

Guirakoo, Pugachev, and Zhang, 2004

WHAT ABOUT HUMANS?WHAT ABOUT HUMANS? Tetravalent Tetravalent

vaccinevaccine ChimeriVax-ChimeriVax-

Dengue?Dengue? 20% 20%

seroconversion rateseroconversion rate

More research More research necessary!necessary!

http://www.lung.ca/pneumonia/images/doc2.gif

PUBLIC HEALTH PUBLIC HEALTH STRATEGIES STRATEGIES

Vector Control Surveillance Preparation for outbreaks Research

NON-BIOLOGICAL MEANS OF DECREASING THE

INCIDENCE OF DENGUE

w3.whosea.org/extrelations/ images/Bed%20net.jpg

MOSQUITO MOSQUITO NETSNETS

NO MORE NO MORE MOSQUITOES!MOSQUITOES!

www.mosquitobarrier.com/ images/tincan.jpg

www.headlice.org/ images/unsanitary.jpg

ABOUT THAT STANDING WATER…

“Children play in sewage in Nairobi's sprawling Mukuru

Kaiyaba slum.”

http://www.alertnet.org/thefacts/reliefresources/108273140124.htm

IMPEDIMENTSIMPEDIMENTS Still lack complete understanding Still lack complete understanding

of dengue virus virulenceof dengue virus virulence Social/socioeconomicSocial/socioeconomic Travel spreads different serotypesTravel spreads different serotypes Demographic changesDemographic changes Decentralized and therefore weak Decentralized and therefore weak

public health systemspublic health systems

REFERENCESREFERENCES ““Arthropod-borne Viruses Infection” Arthropod-borne Viruses Infection”

http://virology-online.com/viruses/Arboviruses7.htmhttp://virology-online.com/viruses/Arboviruses7.htm (accessed on April 2, (accessed on April 2, 2005).2005).

““Bioterrorism Agents/Diseases” (2004). www.bt.cdc.gov/agent/agnetlist-Bioterrorism Agents/Diseases” (2004). www.bt.cdc.gov/agent/agnetlist-category.aspcategory.asp (accessed (accessed on April 12, 2005).on April 12, 2005).

““Bleeding Into the Skin.” (2003). Bleeding Into the Skin.” (2003). http://www.nlm.nih.gov/medlineplus/ency/article/003235.htm (accessed on http://www.nlm.nih.gov/medlineplus/ency/article/003235.htm (accessed on April 12, April 12, 2005).2005).

““Capillary Fragility Test.” (1998). Capillary Fragility Test.” (1998). http://www.healthcentral.com/mhc/top/003395.cfmhttp://www.healthcentral.com/mhc/top/003395.cfm (accessed (accessed on April 5, on April 5, 2005).2005).

CDC Dengue Fever Homepage. (2005). CDC Dengue Fever Homepage. (2005). http://www.cdc.gov/ncidod/dvbid/denguehttp://www.cdc.gov/ncidod/dvbid/dengue. (accessed . (accessed on March 3, 2005).on March 3, 2005).

CDC Slideshow. (1999). “Dengue: Virus, Vector, and Epidemiology.” CDC Slideshow. (1999). “Dengue: Virus, Vector, and Epidemiology.” http://phil.cdc.gov/PHIL_Images/08051999/00004/dengue_phf/sld006.htm

(accessed on April 1, 2005) Chambers, T.J., Y. Liang, D.A. Droll, J.J. Schlesinger, A.D. Davidson, P.J. Chambers, T.J., Y. Liang, D.A. Droll, J.J. Schlesinger, A.D. Davidson, P.J.

Wright, X. Jiang Wright, X. Jiang (2003). Yellow Fever Virus/Dengue-2 Virus and Yellow Fever (2003). Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus/Dengue-4 Virus Virus Chimeris: biological characterization, Chimeris: biological characterization, immunogenicity, and protection against dengue immunogenicity, and protection against dengue encephalitis in the mouse encephalitis in the mouse model. Journal of Virology. model. Journal of Virology. 7777:3655-3668.:3655-3668.

““Dengue Triad.” (2005). Dengue Triad.” (2005). http://www.healthatoz.com/healthatoz/Atoz/ency/dengue_fever.jsp. (accessed http://www.healthatoz.com/healthatoz/Atoz/ency/dengue_fever.jsp. (accessed on on March 31, 2005).March 31, 2005).

REFERENCESREFERENCES ““Dengue Virus Profile.” (2000). Dengue Virus Profile.” (2000).

http://www.stanford.edu/group/virus/flavi/2000/dengue.htm. (accessed on http://www.stanford.edu/group/virus/flavi/2000/dengue.htm. (accessed on April 4, April 4, 2005).2005).

Guirakhoo, F., K Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Guirakhoo, F., K Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Lang, S. Ocran, F. Mitchell, M. Parsons, N. Brown, S. Brandler, C. Mitchell, M. Parsons, N. Brown, S. Brandler, C. Fournier, B. Barrere, F. Rizvi, A. Fournier, B. Barrere, F. Rizvi, A. Travassos, R. Nichols, D. Trent, and T. Travassos, R. Nichols, D. Trent, and T. Monath. (2004). Safety and efficacy of chimeric Monath. (2004). Safety and efficacy of chimeric yellow fever-dengue virus yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. tetravalent vaccine formulations in nonhuman primates. Journal of Journal of

Virology. Virology. 7878:4761-4775.:4761-4775. Halstead, S.B. (1988). Pathogenesis or dengue: challenges to molecular Halstead, S.B. (1988). Pathogenesis or dengue: challenges to molecular

biology. Science. biology. Science. 239:239:476-481.476-481. ““Hemorrhagic Fevers.” 2005. Hemorrhagic Fevers.” 2005.

http://www.healthatoz.com/healthatoz/Atoz/ency/hemorrhagicfevers.jsp http://www.healthatoz.com/healthatoz/Atoz/ency/hemorrhagicfevers.jsp (accessed on (accessed on April 3, 2005).April 3, 2005).

Ho, L., J. Wang, M Shaio, C. Kao, D. Chang, S. Han, and J. Lai. (2001). Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. The Journal of Immunology. 166:1499-1506.

Kalayanarooj, S. (1999). Standardized clinical management: evidence of reduction in dengue hemorrhagic fever child fatality rate in Thailand. Dengue Bulletin. 23. http://w3.whosea.org/en/section10/section332/section521_2449.htm (accessed on April 2, 2005).

REFERENCESREFERENCES Kao, C., C. King, D. Chao, H. Wu, and G. Chang. (2005). Laboratory diagnosis

of dengue virus infection: current and future perspectives in clinical diagnosis and public health. J. Microbiol. Immunol. Infect. 38: 5-16.

Kuhn, R.J., W. Zhang, M.G. Rossmann, S.V. Pletney, J. Corver, E. Lenches, C.T. Jones, S. Mukhopadhyay, P.R. Chipman, E.G. Strauss, T.S. Baker, and J.H. Strauss. (2002). Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell Press. 108:717-725.

Lai, P., S. Lee, C. Kao, Y. Chan, C. Huang, W. Lia, S. Wann, H. Lin, M Yen, and Y. Liu. (2004). Characteristics of a dengue hemorrhagic

fever oubreak in 2001 in Kaohsiung. J. Microbiol. Immunolo. Infect. 37: 266-270.

“Lymph Nodes.” www.cancerhelp.org.uk/cancer_images/nodesta.gif (accessed on April 1, 2005).

Mady, B.J., D.V. Erbe, I. Kurane, M.W. Fanger, and F.A. Ennis. (1991). Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. Journal of Immunology. 147:3139- 3144.

Modis, Y., S. Ogata., D. Clements, S. Harrison. (2004). Structure of the dengue virus envelope protein after membrane fusion. Nature. 427:313-318.

Perez, J., A Vorndam, and G. Clark. (2001). The dengue and dengue hemorrhagic fever epidemic in Puerto Rico, 1994-1995. Am. J. Trop. Med. Hyg. 64: 67-74.

““Petechiae.” (2001). http://www.healthopedia.com/petechiae/ (accessed on Petechiae.” (2001). http://www.healthopedia.com/petechiae/ (accessed on April 3, 2005).April 3, 2005).

Shepherd, S., P. Hinfrey, and W.H. Shoff. (2002). Dengue Fever. http://www.emedicine.com/MED/topic528.htm. (accessed April 12, 2005).

Shrivastava, R. (2004). Dengue haemorrhagic fever: a global challenge. Indian Journal of Medical Microbiology. 22:5-6.

REFERENCESREFERENCES Shu, P. and J. Huang. (2004). Current advances in dengue diagnosis.

Clinical and Diagnostic Laboratory Immunology. 11:642-650. Stephenson, J. (2005). Understanding dengue pathogenesis: implications

for vaccine design. Bulletin of the WHO. 83: 308-314. Sun, W., R. Edelman, N. Kanesa-Thasan, K.H. Eckels, J.R. Putnak, A.D.

King, H. Houng, D. Tang, J. M. Scherer, C.H. Hoke, and B. Innis. 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69: 24-31.

““Thrombocytopenia.” (2005). Thrombocytopenia.” (2005). http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm (accessed on April 2, 2005).(accessed on April 2, 2005).

World Health Organization. (2002). Dengue: Strategic direction for research. www.who.int.tdr. (accessed on March 20, 2005).

World Health Organization. (1999). Regional guidelines on dengue/DHF Prevention and Control: Clinical manifestations and diagnosis. http://w3.whosea.org/en/section10/section332/section554_2564.htm (accessed on April 1, 2005).

Wilson, M. and L. Chen. (2002). Dengue in the Americas. Dengue Bulletin. 26: 44-61.